UK healthcare and pharma services M&A activity rose sharply in the first quarter of 2026, with 114 deals completed — a 37% uplift on the same period in 2025, according to Grant Thornton's Healthcare and Pharma Services M&A Review for Spring 2026. Private equity and venture capital-backed transactions led the acceleration, rising 43% year-on-year as financial investors continued to back the sector's defensive resilience and structural long-term growth characteristics.
The increase was partly attributable to a catch-up effect — political uncertainty and a late Autumn Budget in 2025 pushed a number of Q4 transactions into the new year. But the underlying momentum was genuine. Diversification away from NHS dependency, growing consumer-facing healthcare demand, and the continuing appeal of niche and highly specialised assets all drove activity across four distinct sub-sectors: medical products and medtech, pharma and life sciences, clinical services and social care.
Source: Grant Thornton Healthcare and Pharma Services M&A Review, Spring 2026. Data: Capital IQ, Zephyr, Mergermarket, Health Investor, LaingBuisson, Grant Thornton UK.Overview — 114 Deals in Q1 2026
"Private equity and venture capital-backed deals were up 43% on Q1 2025, as financial investors backed the sector's defensive resilience and structural growth."
The headline figure of 114 deals in Q1 2026 represents a materially stronger start to the year than 2025, and reflects several converging dynamics. Providers increasingly used acquisition as a route to diversify away from NHS dependency — with funding constraints, insourcing pressures and restrictions to the right-to-choose framework all prompting healthcare businesses to explore corporate health, private provision and international markets as alternative revenue streams.
Public market and IPO activity remained limited, but private equity appetite for listed healthcare companies stayed strong — a theme that recurred across all four sub-sectors and that is discussed in detail below.
For investors assessing the UK healthcare M&A market in 2026, the Q1 data confirms that deal flow is robust, buyer competition is intensifying around niche assets, and the structural drivers of healthcare consolidation — demographic demand, NHS capacity constraints, fragmented markets and the appeal of alternative healthcare investments with non-cyclical revenue profiles — remain firmly in place.
Medical Products and MedTech
The medtech and medical products sub-sector saw sustained activity throughout Q1 2026, characterised by a strong preference among both trade and financial buyers for highly specialised niche businesses — a theme that cut across deal sizes.
Key Transactions
In April 2026, Grant Thornton advised Pennamed — a specialist distributor of endoscopic consumables — on its sale to Swedish company Getinge. The process was highly competitive, reflecting Pennamed's strong margins and clear clinical specialism. The deal illustrated what has become a consistent pattern across UK healthcare M&A: assets with a well-defined niche, even at smaller scale, are attracting competitive processes and premium multiples.
Swedish life science company AddLife continued its buy-and-build strategy in March 2026, acquiring UK device distributor BioSpectrum. Belgian investment holding company Groupe Bruxelles Lambert (GBL) signed an agreement in February to acquire a controlling stake in Rayner Surgical Group — a transaction that GBL itself characterised as reflecting the healthcare sector's favourable long-term demographic trends, growth perspectives and geographic fragmentation as a platform for value-creative M&A.
In digital health and NHS transformation technology, London-based healthcare-focused private equity firm G Square made two acquisitions through its health tech platform Mayden — patient engagement platform Wellola and NHS AI-Scribe firm CLAI. Rockpool Investments acquired CareScribe, a dictation and captioning software company. Healthtech startup Emerald secured pre-seed funding for its GP-led preventative care model.
The investment in NHS digital transformation technology reflects the Government's 10 Year Health Plan for England, which outlines the shift from analogue to digital as one of three structural priorities — creating a sustained demand environment for HCIT and medtech businesses providing the enabling infrastructure.
Pharma and Life Sciences
Pharma and life sciences M&A rebounded in Q1 2026 after a quieter Q4 2025. The sub-sector's defining characteristic in the quarter was buyer willingness to pursue smaller, highly specialised businesses for strategic reasons — particularly those with depth of clinical expertise, specificity of IP or established market access capability. This pattern is consistent with the broader patent cliff dynamics driving specialty pharma M&A globally, where acquirers are increasingly prioritising de-risked, commercially validated assets over earlier-stage development-stage businesses.
Ongoing biotech funding pressures and tariff uncertainty pushed investor attention toward services and consultancies rather than early-stage development businesses — a shift that reflects the maturing of the UK life sciences investment landscape and the growing recognition of pharma services as an alternative healthcare investment with more predictable revenue and lower binary risk than drug development.
The growing influence of AI across the pharma and life sciences sector is also increasingly affecting valuations — with AI capability and data infrastructure treated as material differentiators in competitive deal processes.
Key Transactions
CBPE Capital invested in Access Infinity, a specialist in pharmaceutical market access and pricing solutions. BGF took a £15 million stake in Seda Pharma Development Services. Bridgepoint-backed Prescient acquired Dolon, a market access specialist, demonstrating continued appetite for access and commercialisation capability.
Axol Bioscience — advised by Grant Thornton — acquired the ophthalmology business of Newcells Biotech in February, reflecting the sub-sector theme of targeted acquisitions of highly specialised scientific assets.
International buyers remained active in targeting UK assets. US-based Red Nucleus Solutions acquired Bridge Medical Consulting — a UK health economics consultancy using AI to enhance its data capabilities — in February, reinforcing the US appetite for UK specialty pharma services businesses with embedded AI capability.
EQT's approach for Oxford Biomedica demonstrated that private equity appetite for listed UK life sciences companies remains a live theme in 2026 — consistent with the broader pattern of PE interest in listed healthcare across multiple sub-sectors.
Clinical Services
Clinical services M&A in Q1 2026 was characterised by two parallel themes: the enduring attractiveness of high-quality, clinician-led services with strong referral networks and long track records; and the growing appeal of consumer-facing healthcare to investors with lifestyle and consumer brand backgrounds.
Key Transactions
Grant Thornton advised Herts & Essex Fertility Centre on its sale to FutureLife Group in March — a PE-backed pan-European acquirer backed by Hartenberg Holding and CVC Capital Partners. The business, founded 40 years ago by a husband and wife clinical team, exemplifies the category of established, clinician-led services that continue to attract institutional capital at premium multiples.
Imbiba's acquisition of Pindrop Hearing — a private clinical audiology business — illustrated the consumer investor angle, consistent with Imbiba's focus on consumer and lifestyle investments. Grant Thornton views this as indicative of a broader opportunity for consumer-focused investors to enter healthcare markets that have historically underinvested in brand and customer experience.
OCL Vision, backed by BGF, acquired Eastbourne Vision. Optima Health agreed to acquire PAM Healthcare, strengthening its position in occupational health. Both transactions reflect continued buy-and-build platform activity in specialist clinical services.
The quarter's most closely watched public markets story was the non-emergence of a takeover for Spire Healthcare. Interest from Bridgepoint and Triton fell away during the quarter, prompting an 18% share price drop for Spire in March 2026. Grant Thornton notes that discussions with other parties are ongoing and further developments are expected later in the year.
Social Care
Social care was the sub-sector most directly affected by the regulatory consequences of 2025's record deal activity. Deal volumes fell sharply — from 40 in Q4 2025 to 19 in Q1 2026 — following Welltower's landmark acquisition of more than 600 UK care homes across four completed transactions: Barchester Healthcare, HC-One, Aria Care (including Asprey) and Danforth Care.
The Competition and Markets Authority opened a formal merger inquiry in January 2026. On 7 May 2026, the CMA concluded its Phase One review and found that each of the four completed acquisitions may give rise to a substantial lessening of competition in local markets. Absent acceptable undertakings from Welltower, all four deals are heading for an in-depth Phase Two investigation.
"If the CMA requires divestments, a number of homes could come to market, creating opportunities for smaller and mid-market acquirers."
The investigation has created a degree of regulatory chill — with some buyers pausing to assess how much consolidation the CMA will tolerate in the care home sector. Welltower's absorption of a large volume of assets has also reduced the number of homes available to trade in the near term. However, if the CMA requires divestments as a condition of approving the transactions, a cohort of care home assets could come to market simultaneously — creating selective acquisition opportunities for smaller and mid-market operators.
Complex dementia care remained active as a sub-sector despite the broader slowdown. Fortava Healthcare, backed by Downing Private Equity, acquired three homes in Nottingham. Further deal activity is expected in Q2 2026, including the recently announced disposal of the Towerview Care portfolio. International capital — attracted by the combination of property-backed assets and structural demand from an ageing UK population — remained present throughout the quarter despite the regulatory headwind.
Grant Thornton also provided financial due diligence for Sovereign Capital Partners' February acquisition of Apollo Home Healthcare, a complex care provider supporting adults and children nationally — one of the more significant individual transactions in the social care sub-sector during the quarter.
Outlook for Q2 2026 and Beyond
Healthcare M&A enters Q2 2026 from a position of genuine strength. The sector's defensive profile, growing end-user demand and fragmented market structure will continue to drive dealmaking throughout the year. Recent sponsor-backed transactions demonstrate that well-structured assets with resilient demand continue to attract competitive financing.
Early Q2 2026 deals include CGEN's acquisitions of St Matthews Healthcare and Cera Care's acquisition of homecare provider My Care — two transactions where trade operators broadened both their service offerings and geographic reach through M&A.
For investors and operators evaluating the UK healthcare M&A landscape, Grant Thornton identifies the businesses most likely to attract capital and competitive processes in the coming quarters: those that are well-positioned in a defined niche, diversified beyond NHS-only revenue, and able to demonstrate clinical quality and operational resilience.
Headwinds remain. Tariff pressures, NHS funding uncertainty and the impact of Middle East disruption on energy and material costs are all live factors that investors must assess. But the structural drivers of healthcare M&A — demographic demand, fragmented markets, the shift from NHS to private provision, and the appeal of healthcare as an alternative healthcare investment category with non-cyclical characteristics — are durable and well-understood by the institutional and private capital now active in the UK market.